| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7704984 | APIL | Extended estrogen dosing contraceptive regimen |
Feb, 2029
(5 years from now) | |
Lo Loestrin Fe is owned by Apil.
Lo Loestrin Fe contains Ethinyl Estradiol; Norethindrone Acetate.
Lo Loestrin Fe has a total of 1 drug patent out of which 0 drug patents have expired.
Lo Loestrin Fe was authorised for market use on 21 October, 2010.
Lo Loestrin Fe is available in tablet;oral dosage forms.
Lo Loestrin Fe can be used as lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.
The generics of Lo Loestrin Fe are possible to be released after 02 February, 2029.
Drugs and Companies using ETHINYL ESTRADIOL; NORETHINDRONE ACETATE ingredient
Market Authorisation Date: 21 October, 2010
Treatment: Lo loestrin fe is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception
Dosage: TABLET;ORAL
LO LOESTRIN FE family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic